Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice by Alderman, J. McKee et al.
Neuroendocrine inhibition of glucose production and resistance
to cancer in dwarf mice
J. McKee Aldermana,1, Kevin Flurkeyb,1, Natasha L. Brooksa, Sneha B. Naika, Jonathan M.
Gutierreza, Urmila Srinivasa, Kristen B. Ziaraa, Linhong Jinga, Gunnar Boysena, Rod
Bronsonb, Simon Klebanovc, Xian Chena, James A. Swenberga, Mats Stridsbergd, Carol E.
Parkera, David E. Harrisonb, and Terry P. Combsa,*
aUniversity of North Carolina, Chapel Hill, NC 27599, USA
bJackson Laboratories, Bar Harbor, ME 04609, USA
cColumbia University, New York, NY 100025, USA
dUppsala University Hospital, SE-75185 Uppsala, Sweden
Abstract
Pit1 null (Snell dwarf) and Proph1 null (Ames dwarf) mutant mice lack GH, PRL and TSH. Snell
and Ames dwarf mice also exhibit reduced IGF-I, resistance to cancer and a longer lifespan than
control mice. Endogenous glucose production during fasting is reduced in Snell dwarf mice compared
to fasting control mice. In view of cancer cell dependence on glucose for energy, low endogenous
glucose production may provide Snell dwarf mice with resistance to cancer. We investigated whether
endogenous glucose production is lower in Snell dwarf mice during feeding. Inhibition of endogenous
glucose production by glucose injection was enhanced in 12 to 14 month-old female Snell dwarf
mice. Thus, we hypothesize that lower endogenous glucose production during feeding and fasting
reduces cancer cell glucose utilization providing Snell dwarf mice with resistance to cancer. The
elevation of circulating adiponectin, a hormone produced by adipose tissue, may contribute to the
suppression of endogenous glucose production in 12 to 14 month-old Snell dwarf mice. We compared
the incidence of cancer at time of death between old Snell dwarf and control mice. Only 18% of old
Snell dwarf mice had malignant lesions at the time of death compared to 82% of control mice. The
median ages at death for old Snell dwarf and control mice were 33 and 26 months, respectively. By
contrast, previous studies showed a high incidence of cancer in old Ames dwarf mice at the time of
death. Hence, resistance to cancer in old Snell dwarf mice may be mediated by neuroendocrine factors
that reduce glucose utilization besides elevated adiponectin, reduced IGF-I and a lack of GH, PRL
and TSH, seen in both Snell and Ames dwarf mice. Proteomics analysis of pituitary secretions from
Snell dwarf mice confirmed the absence of GH and PRL, the secretion of ACTH and elevated
secretion of Chromogranin B and Secretogranin II. Radioimmune assays confirmed that circulating
Chromogranin B and Secretogranin II were elevated in 12 to 14 month-old Snell dwarf mice. In
summary, our results in Snell dwarf mice suggest that the pituitary gland and adipose tissue are part
of a neuroendocrine loop that lowers the risk of cancer during aging by reducing the availability of
glucose.
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Snell dwarf mice are valuable laboratory models for investigating the mechanisms of cancer
and aging. Snell dwarf mice are homozygous for the Pit1dw allele, which eliminates function
of the transcription factor Pit1 (Li et al., 1990). Snell dwarf mice are deficient in growth
hormone (GH), prolactin (PRL) and thyroid stimulating hormone (TSH) due to hypoplasia of
the cells that produce these hormones in the anterior pituitary. Snell dwarf mice are resistant
to chemically induced cancers and live longer than control mice which are either homozygous
or heterozygous for the wild-type Pit1 allele (Flurkey et al., 2001; Rennels et al., 1965;
Bielschowsky and Bielschowsky, 1959).
During fasting, endogenous glucose production and whole-body glucose utilization are lower
in Snell dwarf mice than in control mice (Brooks et al., 2007). The reduction of endogenous
glucose production may deprive cancer cells of energy and provide resistance to cancer. Rather
than oxidative phosphorylation, cancer cells depend on glycolysis for ATP production and
therefore rely on high levels of glucose for energy (Matoba et al., 2006; Brown, 1999; Gullino
et al., 1967). Glucose deprivation causes cancer cells in culture to undergo cell death more
readily than healthy cells (Funes et al., 2007; Elstrom et al., 2004; Shim et al., 1998). Elevated
circulating glucose increases the risk of cancer and reduces the effectiveness of medical
treatment in cancer patients (Caudle et al., in press; Stattin et al., 2007; Malin et al., 2005).
Low endogenous glucose production was previously reported in Snell dwarf mice during
fasting (Brooks et al., 2007). Therefore, the first goal of this study was to determine whether
increased inhibition of endogenous glucose production in Snell dwarf mice extends to the fed
state. Glucose metabolism differs dramatically between the fed and fasted states. In the fed
state (a) circulating levels of glucose and insulin are elevated, (b) the fraction of glucose in the
circulation from the gastrointestinal tract is elevated, (c) circulating glucose is stored and used
for energy and (d) glucose production from gluconeogenesis and glycogenolysis is not needed
to replenish the disappearance of circulating glucose.
Hypophysectomy, surgical removal of the pituitary gland, was used as endocrine therapy to
reduce hormone action before highly specific chemicals and monoclonal antibodies were
available for the treatment of cancer (Luft et al., 1955). A lack of GH and low levels of insulin
like growth factor I (IGF-I), a hormone secreted mainly by GH stimulation, play a key role in
resistance to cancer. GH deficient rats are highly resistant to chemical induction of cancer
unless GH is replaced (Shen et al., 2007). The suppression of IGF-I could provide resistance
to cancer by reducing glucose utilization (Rossetti et al., 1991).
Resistance to cancer in Snell dwarf mice can also be mediated by the elevation of circulating
adiponectin (Brooks et al., 2007; Combs et al., 2003). Adiponectin, a hormone produced
exclusively by adipocytes, inhibits endogenous glucose production (Brooks et al., 2007; Combs
et al., 2004; Combs et al., 2001). Adiponectin inhibits endogenous glucose production by the
liver through the suppression G6Pase and PEPCK, rate limiting enzymes in hepatic glucose
production (Combs et al., 2001). Numerous clinical studies suggest that breast cancer risk is
decreased by elevated circulating adiponectin (Chen et al., 2006; Korner et al., 2007; Mantzoros
et al., 2004; Miyoshi et al., 2003; Tworoger et al., 2007).
Elevated adiponectin has been reported in several GH deficient and long-lived mouse models
(Berryman et al., 2004; Combs et al., 2003; Wang et al., 2006). Adiponectin inhibits
endogenous glucose production and stimulates fatty acid utilization through its intracellular
target, AMP activated protein kinase (AMPK) (Brooks et al., 2007; Nawrocki et al., 2006;
Tomas et al., 2002; Yamauchi et al., 2002). AMPK is also implicated in the enhancement of
fatty acid metabolism through exercise training (Winder, 2001). Gene expression array data in
GH deficient mice, such as the Snell dwarf, Ames dwarf, GH release hormone receptor-null
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(little) and GH receptor-null mice, support the conclusion that fatty acid oxidation is elevated
in these long-lived and cancer resistant mouse models (Stauber et al., 2005).
Ames dwarf mice are homozygous for the Prop1df allele which leads to the loss of the
transcription factor Prop1 (Sornson et al., 1996). Prop1 regulates the expression of Pit1 and,
as a result, Ames dwarf mice are deficient in GH, PRL and TSH similar to Snell dwarf mice.
Ames dwarf mice live longer than control mice which are either homozygous or heterozygous
for the wild-type Prop1 allele (Brown-Borg et al., 1996). The median age of death for Ames
dwarf and control mice is 36 and 26 months, respectively; however, despite having a similar
endocrine profile as Snell dwarf mice, old Ames dwarf mice exhibit a high incidence of cancer
at the time of death (Ikeno et al., 2003). Necropsy at the time of death revealed malignant
lesions in 72% of Ames dwarf mice, in comparison to 95% of control mice. Although young
Snell dwarf mice exhibit resistance to chemically induced tumors, data on naturally occurring
cancers in old Snell dwarf mice is currently not available. Thus, our second goal was to
determine whether old Snell dwarf mice also have a high incidence of cancer at the time of
death similar to Ames dwarf mice.
After discovering greater inhibition of endogenous glucose production by intravenous injection
of glucose (aim 1) and resistance to cancer at the time of death in old Snell dwarf mice (aim
2), we applied proteomics analysis to determine whether the pituitary of Snell dwarf mice
overproduces or lacks other hormones besides GH, PRL and TSH that may play a role in the
resistance to cancer (aim 3). Therefore, our third and final goal was to compare the proteins
secreted from the pituitaries of Snell dwarf and control mice. Previous proteomics analyses of
whole anterior pituitaries from outbred mice verified production of all known pituitary
hormones except for THS (Blake et al., 2005). The effect of the Snell dwarf mutation on
pituitary secretions has not been previously examined by proteomics analysis.
2. Materials and methods
2.1. Mice
Unless otherwise indicated, 12 to 14 month-old female mice in the F1 (DW/J × C57Bl/6J)
background were used. Mice were housed in ventilated isolator cage systems in a pathogen-
free isolator barrier facility at 23 °C, 55% humidity on a 12-h light/12-h dark cycle. Mice
received a standard chow diet consisting of 73% carbohydrate, 18% protein, 4% fat and 5%
ash (Purina). Mice were sacrificed by cervical dislocation for experiments requiring dissection
of tissues. Experimental procedures were approved by the Institutional Animal Care and Use
Committees at the University of North Carolina.
2.2. Intravenous glucose tolerance test
Mice were fasted after 7 am and studied between 1 and 3 pm. In the afternoon, mice received
a single intravenous injection of glucose (0.8 mg/g body weight) mixed with tritium labeled
glucose (D-[3-3H]glucose; 3H on carbon 3 of glucose) from Amersham Biosciences (Beard et
al., 1986). The mixture was injected directly into the circulation through the ophthalmic plexus
of conscious free-moving mice. The tail was nicked 2–4 mm from the tip, always below the
end of the vertebrae. Blood samples (10–20 µL) were collected from the tail tip at 2.5, 5, 10,
20 and 30 min after injection for measurement of glucose and radioactivity as previously
described (Brooks et al., 2007). The fraction of circulating glucose representing the injected
glucose was calculated from the specific activity of the injected [3H]glucose/glucose solution
(3 × 105 cpm/mg glucose). HPLC analysis was performed to verify that the radioactivity
measured in dried plasma by scintillation counter represented [3H]glucose. An Agilent 1100
HPLC system connected to a beta-RAM Model 2B Detector (IN/US Systems) was used. An
Aminex HPX-87C polystyrene divinylbenzene resin column (Bio-Rad) was used at 80 °C using
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a 0.6 mL/min flow of water. Mutant and control mice were always paired for the intravenous
glucose tolerance test.
2.3. Cancer evaluation at necropsy
Gross pathologic examination was performed while gathering life span data at the Jackson
Laboratories. Necropsy was performed on female Snell dwarf mice and control mice from a
cohort of F1 (DW × C3He) mice. Cages were checked daily and necropsy was performed
immediately when a dead mouse was found. The median age at time of death was 33 months
for Snell dwarf mice and 26 months for control mice. A total of 11 Snell dwarf and 38 control
mice underwent necropsy. Histology was used to determine whether neoplastic lesions were
benign or malignant.
2.4. Proteomics analysis of pituitary secretions
Anterior pituitary glands from 12 to 14 month-old Snell dwarf and age-matched control mice
were placed in serum-free modified Eagle’s medium immediately after dissection and
incubated at 37 °C for 1 h. The media was transferred to new tubes and centrifuged at 45,000
rpm for 1 h. Proteomics analyses were performed at the UNC-Duke Proteomics Center. The
supernatant was digested with trypsin at 37 °C for 1 h and analyzed by nano LC/MS/MS on a
ThermoFisher Orbitrap hybrid FT-MS, equipped with an Eksigent nanoLC system, New
Objective nanospray source and a nanobore PicoFrit column (ProteoPep™ II C18, 50 lm id ×
10.0 cm, 10 µm tip size, New Objective). The Orbitrap data were processed using
ThermoFisher’s Bioworks 3.3.1 software, the Sequest search engine and the FASTA Protein
Database. A comprehensive report of the protein functions was prepared using BLAST on the
NCBI database. Protein expression ratios were determined with GE Healthcare’s Decyder MS
software (Johansson et al., 2006).
2.5. PCR reactions
Genotyping of Pit1dw allele carriers for breeding. The Pit1dw allele was detected from tail DNA
to identify heterozygous breeding pairs by PCR using AGCTGCTAAGGATGCTCTGG
(forward primer), CTCTGCCTTCGGTTGCAGAAA (reverse primer) and PlatTAQ
(Invitrogen) under standard PCR conditions. The reverse primer was designed to detect the
point mutation of Pit1dw allele (Li et al., 1990). Reverse Transcriptase PCR. Mice were
sacrificed by cervical dislocation between 1 and 3 pm. Tissues were frozen in liquid nitrogen
immediately after dissection and stored at 4 °C in RNA-Later (Ambion). RNA was isolated
using a kit (Qiagen) according to the manufacturer’s protocol. Yield and purity were
determined by spectrophotometric absorption analysis at 260/280 nm and gel electrophoresis.
cDNA was prepared with reverse transcriptase (Invitrogen) and random hexamers. The PCR
primer pair sequences were AAGAGGCCTGAGTGCCCAAC and
ACGCTCCTCCTCCTCTTCC for Chromogranin A, GACCAGGACCAGAGCCAG and
GACCAGGACCA GAGCCAG for Chromogranin B and GCAGTGGGAGGTCACAGAG
and ATACCCACCCTTGGAGAGC for Secretogranin II.
2.6. Northern blot analysis
Total RNA (5 µg) was electrophoresed on 1.2% agarose/6% formaldehyde gel and transferred
to Hybond-XL membrane (Amersham Biosciences). RNA was cross-linked to the membrane
by ultraviolet irradiation and incubated overnight at 65 °C in hybridization buffer (Amersham
Biosciences) mixed with radiolabeled DNA probe. Membranes were washed with 3× SSC,
exposed to a PhosphorImager (Molecular Dynamics) screen for 24 h, and analyzed on a
PhosphorImager using ImageQuant Software. Probe Synthesis. Radiolabeled probes were
prepared by PCR using 2.5 mM[32P]dCTP (Perkin Elmer). The Secretogranin II probe was
prepared using TGCTGAAACGGCCCGAGC and CAGGCGTGTCCACTGGGAA. The
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Chromogranin B probe was prepared using TGCTGAAACGGCCCG AGC and
CAGGCGTGTCCACTGGAA. An oligonucleotide CTTCC
TCTAGATAGTCAAGTTCGACCGTCT specific for 18S RNA was end labeled with [32P]
dATP using T4 polynucleotide kinase (Invitrogen) and used to confirm equal RNA loading.
2.7. Hormone measurements
Adiponectin was measured in plasma from control and Snell dwarf mice by Western blot
analysis as previously described (Brooks et al., 2007). Adiponectin was measured using rabbit
anti-sera to murine adiponectin amino acid sequence 18–32 (mAC-RP30: 18–32) (Scherer et
al., 1995). Chromogranin A, Chromogranin B and Secretogranin II were measured by
radioimmune assay. Chromogranin A was measured using an antibody to human
Chromogranin A amino acid sequence 324–337 (hCgA:324–337), which detects the WE-14
region of Chromogranin A (Stridsberg et al., 2004). Chromogranin B was measured using an
antibody to human Chromogranin B amino acid sequence 312–331 (hCgB:312–331)
(Stridsberg et al., 2005). Secretogranin II was measured using an antibody against the human
Secretogranin II amino acid sequence 154–165 (hSgII:154–165) (Stridsberg et al., in press).
The antibodies used for the measurements of granins have been tested for inter-species cross
reactivity; all measure rodent granins with 100% cross reactivity. The detection limits were 10
fmol and the total assay variation was 10% for all assays.
3. Results
3.1. Glucose metabolism in Snell dwarf mice
Low endogenous glucose production and whole-body glucose utilization were previously
reported in Snell dwarf mice in the fasted (Brooks et al., 2007). Rather than the fasted state,
the current data were obtained under conditions simulating the fed state (Fig. 1). Control and
Snell dwarf mice received a single intravenous injection of glucose (0.8 mg/g body weight)
mixed with trace amounts of [3H]glucose (3 × 105 cpm/mg glucose). Although plasma glucose
levels were increased after glucose injection, they were lower in Snell dwarf than control mice
at 2.5, 5, 10, 20 and 30 min. Endogenous glucose levels were suppressed after glucose injection,
however they were reduced further in Snell dwarf than control mice at 2.5, 5, 10, 20 and 30
min. Thus, increased inhibition of glucose production in Snell dwarf mice in the fed state may
restrict glucose utilization by cancer cells and thereby prevent cancer.
3.2. Incidence of cancer at time of death in old Snell dwarf mice
Snell dwarf mice are resistant to chemically induced cancers; however, the incidence of cancer
at the time of death in old Snell dwarf mice has not been previously described (Rennels et al.,
1965; Bielschowsky and Bielschowsky, 1959). We observed that significantly fewer old Snell
dwarf mice had neoplastic lesions at necropsy. Only 18% of Snell dwarf mice had one or more
malignant lesions at the time of death, compared to 82% of control mice (Fig. 2). These results
are in contrast with previous evidence of high tumor incidence at time of death in old Ames
dwarf mice (Ikeno et al., 2003).
3.3. Adiponectin levels in Snell dwarf mice
Adiponectin is a hormone that inhibits endogenous glucose production (Brooks et al., 2007;
Combs et al., 2004, 2001). If elevated adiponectin protects Snell dwarf mice from cancer by
reducing glucose production, adiponectin must remain elevated in older mice. Elevation of
plasma adiponectin was previously reported in 3 to 6-month old Snell dwarf and Ames dwarf
mice (Brooks et al., 2007; Wang et al., 2006; Combs et al., 2003). We found that plasma
adiponectin was also elevated in 12 to 14 month-old Snell dwarf mice indicating a possible
role for adiponectin in cancer resistance (Fig. 3). Of course, if elevated adiponectin causes the
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difference in resistance to cancer between Snell and Ames dwarf mice, we predict that
adiponectin will be higher over the lifespan of Snell dwarf than Ames dwarf mice.
3.4. Proteomics analysis of Snell dwarf pituitary secretions
Proteomics analysis was applied to determine whether there are any additional endocrine
differences between Snell dwarf and control mice. Pituitary secretions were collected from
Snell dwarf and control mice ex vivo. Proteomics analysis confirmed the pituitary gland of the
Snell dwarf mouse produces ACTH but not GH or PRL. In addition, the analysis revealed the
Snell dwarf pituitary produces Chromogranin A, Chromogranin B and Secretogranin II (Table
1). The analysis identified a total of 107 proteins from control mouse pituitaries and 52 proteins
from Snell dwarf pituitaries including nuclear, metabolic, protein structure, cell structure,
signaling and secreted proteins. Detection of cellular proteins among pituitary secretions was
indicative of ex vivo pituitary cell lysis. Decyder MS software analysis indicated that
Chromogranin A, Chromogranin B and Secretogranin II were elevated based on matching
peptide masses and retention time.
3.5. Chromogranin A, Chromogranin B and Secretogranin II
The pituitary gland expresses Chromogranin A, Chromogranin B and Secretogranin II mRNA
(Grino et al., 1989; Nicol et al., 2002; Wei et al., 1995). PCR reactions were performed for
Chromogranin A, Chromogranin B and Secretogranin II mRNA expression using pituitary
cDNA from control and Snell dwarf mice. PCR results showed that Chromogranin A,
Chromogranin B and Secretogranin II mRNA were expressed in Snell dwarf and control
pituitaries (data not shown). Primer pair sequences are provided in Materials and Methods.
Circulating levels of Chromogranin A, Chromogranin B and Secretogranin II were measured
in control and Snell dwarf mice by radioimmune assay (Stridsberg et al., 2004, 2005, in
press). Significantly elevated circulating Chromogranin B and Secretogranin II levels were
detected in Snell dwarf mice at p < 0.05 by nonparametric Student t-test (Fig. 4A).
The elevation of circulating Chromogranin B and Secretogranin II led us to investigate whether
the pituitary is a major determinant of these circulating proteins (Fig. 4B). Northern blot
analysis for mRNA expression suggested that the pituitary and the adrenal glands are the major
determinants of circulating Chromogranin B while Secretogranin II was expressed
ubiquitously.
4. Discussion
Our main finding was that endogenous glucose production is inhibited further after glucose
injection in Snell dwarf mice than age-matched controls. Inhibition of endogenous glucose
production by injection of glucose is simulating the fed state. These results complement the
previous data showing suppressed endogenous glucose production during fasting in Snell dwarf
mice (Brooks et al., 2007). The decrease in glucose production could restrict glucose utilization
by cancer cells and inhibit the development of malignant lesions that appear with high
frequency with aging. Diabetes is often associated with elevated glucose production (Basu et
al., 2005; Natali and Ferrannini, 2006; Radziuk and Pye, 2002; Stefan et al., 2003; Wajngot et
al., 2001) and in a recent clinical study, not a single diabetic colorectal cancer patient showed
a complete pathologic response to treatment (Caudle et al., in press).
Also, significantly fewer old Snell dwarf mice had neoplastic lesions at necropsy. Our study
showed that only 18% had one or more malignant lesions, compared to 82% of control mice
at time of death. The low incidence of cancer in Snell dwarf mice is in contrast to the high
incidence of cancer at time of death in old Ames dwarf mice (Ikeno et al., 2003). Necropsy
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revealed that 72% of Ames dwarf mice showed at least one fatal neoplastic lesion at the time
of death, compared to 95% of control mice. The difference in genetic background between
Snell mice used in the present study and Ames dwarf mice is probably not the reason for the
difference in cancer resistance as controls for both models show similar susceptibility to cancer.
Catecholamines, glucagon and glucocorticoids are hormones that stimulate endogenous
glucose production (Kraus-Friedmann, 1984). Adiponectin, a hormone produced by adipose
tissue, inhibits glucose production (Brooks et al., 2007; Combs et al., 2004, 2001; Berg et al.,
2001). Adiponectin can lower cancer cell glucose utilization by inhibiting liver production of
glucose (Fig. 5). The elevation of circulating adiponectin in Snell dwarf mice is an endocrine
signal that suppresses endogenous glucose production and elevates fatty acid oxidation.
Elevated utilization of fatty acids for energy, fat burning, may be associated with a higher level
of fitness compared to elevated utilization of carbohydrates (Brooks et al., 2007).
In the present study, Snell dwarf and control mice received the same dose of glucose per unit
body weight for the intravenous glucose tolerance test. Striking differences in nutrient
metabolism are observed in Ames dwarf and control mice despite similar daily food intake per
body weight (Argentino et al., 2005; Dominici et al., 2003; Hauck et al., 2001; Mattison et al.,
2000; Borg et al., 1995). Elevated glucose utilization for energy can increase oxidative stress
(Nishikawa et al., 2000). Carbohydrate conversion to fatty acids and the oxidation of fatty acids
for ATP may increase longevity in Snell dwarf mice by reducing oxidative stress (Brooks et
al., 2007). Furthermore, the switch in whole-body substrate utilization may impair cancer cell
growth and proliferation.
Glucose utilization can also be reduced in Snell dwarf mice by other mechanisms in addition
to greater inhibition of endogenous glucose production. IGF-I and thyroid hormone deficiency
in Snell dwarfs could lower tissue demand for glucose (Itoh et al., 2001; Rossetti et al.,
1991). Snell dwarf mice also show elevated insulin sensitivity as indicated by circulating
glucose and insulin levels and by glucose and insulin tolerance tests (Brooks et al., 2007;
Combs et al., 2003; Mirand and Osborn, 1953, 1952). The elevation of insulin sensitivity lowers
circulating insulin levels which can reduce GLUT4 mediated transport by insulin responsive
tissues, mainly muscle and adipose (DeFronzo et al., 1981; Rossetti et al., 1997).
The neuroendocrine basis for resistance to cancer in old Snell dwarf mice is currently unknown
but is obviously linked the loss of function of the Pit1 gene. Pit1 overexpression is associated
with transformation, proliferation and tumor growth. Pituitary adenomas show greater
expression of Pit1 than healthy pituitaries (Asa et al., 1993; Delhase et al., 1993; Sanno et al.,
1996). Pit1 overexpression in human breast adenocarcinoma stimulates GH production, cell
growth and cell proliferation (Gil-Puig et al., 2005). Pit1 antisense oligonucleotides reduce GH
mRNA expression and [3H]thymidine incorporation in pituitary somatotrophs and lactotrophs,
suggesting that Pit1 stimulates DNA replication and cell proliferation (Castrillo et al., 1991).
By contrast, the potential role of Pit1 as a tumor suppressor may be limited to somatotrophs
(Canibano et al., 2007).
As a first step towards determining the neuroendocrine basis for the difference in the incidence
of cancer between old Snell and Ames dwarf mice, we tested whether there are any other
pituitary hormone differences in Snell dwarf mice besides a lack of GH, PRL and TSH.
Proteomics analysis and revealed that pituitary secretion of Chromogranin A, Chromogranin
B and Secretogranin II were elevated in Snell dwarf mice. Chromogranin A, Chromogranin B
and Secretogranin II constitute the main members of a unique family of secretory proteins
(Helle, 2004). The effects of Chromogranin A, Chromogranin B and Secretogranin II on
endogenous glucose production are unknown however other effects on glucose metabolism
have been reported. Chromogranin A and Chromogranin B inhibit insulin secretion therefore
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they can lower glucose utilization by insulin responsive tissues (Schmid et al., 2007; Karlsson
et al., 2000; Rossetti et al., 1997). GLUT4 colocalizes with Secretogranin II in large dense core
vesicles (Hudson et al., 1993). Our plasma measurements revealed that circulating levels of
Chromogranin B and Secretogranin II are elevated in Snell dwarfs. Of course, if the elevation
of Chromogranin B and Secretogranin II is responsible for the differences in cancer incidence
between Snell dwarf and Ames dwarf mice, then these hormones should not be elevated in the
Ames dwarf.
It is of great interest to determine the mechanisms that reduce cancer in old Snell dwarf mice,
as they may suggest clinical interventions. Thus, future studies will determine whether
adiponectin, Chromogranin B and Secretogranin II play a role in the inhibition of endogenous
glucose production and resistance to cancer with old age. Fig. 5 illustrates an endocrine link
between the pituitary gland, adipose tissue and the liver that can provide resistance to cancer
by restricting endogenous glucose production. Although it is not indicated in Fig. 5, the anterior
pituitary gland is under the influence of the hypothalamus; the liver’s ability to produce glucose
is also directly inhibited by the hypothalamus through the hepatic branch of the vagus nerve
(Pocai et al., 2005). The low incidence of cancer in Snell dwarf mice should be investigated
further considering the mechanism is related to neuroendocrine factors other than an absence
of GH and IGF-I.
Abbreviations
ACTH adrenalcorticotropic hormone
AMPK AMP activated protein kinase
FSH follicle stimulating hormone
GH growth hormone
GLUT4 glucose transporter 4
IGF-I insulin like growth factor I
LH luteinizing hormone
PRL prolactin
SEM standard error of the mean
TSH thyroid stimulating hormone
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Endogenous glucose in 12 to 14 month-old female Snell dwarf mice after glucose injection.
Control and Snell dwarf mice were injected with glucose (0.8 mg/g body weight) mixed with
trace amounts of [3H]glucose (3 × 105 cpm/mg glucose). Compared to control mice, plasma
glucose was reduced in Snell dwarf mice at 2.5 5, 10, 15, 20 and 30 min after injection,
indicating elevated glucose tolerance. Endogenous glucose in plasma was also reduced in Snell
dwarf mice at 2.5, 5, 10, 15, 20 and 30 min after injection, indicating greater inhibition of
endogenous glucose production. Results are shown as means ± SEM. *, **Significantly
different at indicated time-points by nonparametric Student t-test between Snell dwarf and
control mice where p < 0.05 and N = 6 mice per group.
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Percentage of old female Snell dwarf mice with neoplastic lesions at time of death. The
percentage of mice with one or more neoplastic lesion at time of death was lower for Snell
dwarf than control mice. The median age at time of death was 26 months for control and 33
months for Snell dwarf mice. Neoplastic lesions identified by histology included histiocytic
sarcoma, lymphoma, mammary adenocarcinoma, fibrosarcoma, hepatocellular carcinoma,
leiomyosarcoma, myelogenous leukemia and hemangiosarcoma. Bar graphs show results as
means ± SEM. *Significantly different by χ2 analysis where p < 0.05 and N = 33 control mice
and N = 11 Snell dwarf mice.
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Circulating adiponectin in 12 to 14 month-old female Snell dwarf mice. Plasma adiponectin
was elevated in Snell dwarf mice by Western blot analysis. Bar graphs show results as means
± SEM. *Significantly different by nonparametric Student t-test where p < 0.05 and N = 6 mice
per group.
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(A) Circulating Chromogranin A, Chromogranin B and Secretogranin II in 12 to 14 month-old
female Snell dwarf mice. Plasma Chromogranin B and Secretogranin II were elevated in Snell
dwarf mice by radioimmune assay. Bar graphs show results as means ± SEM. *Significantly
different by nonparametric Student t-test where p < 0.05 and N = 15 mice per group for
Chromogranin A and N = 5 mice per group for Chromogranin B and Secretogranin II. (B)
Tissue Chromogranin B and Secretogranin II mRNA expression by Northern blot analysis in
wild-type mice. Chromogranin B mRNA expression was detected in the pituitary and the
adrenal glands while Secretogranin II mRNA expression was detected ubiquitously.
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Neuroendocrine inhibition of endogenous glucose production and resistance to cancer. Snell
dwarf mice show elevated adiponectin, Chromogranin B and Secretogranin II and low
endogenous glucose production. Furthermore, Snell dwarf mice are highly resistant to cancer.
Adiponectin, Chromogranin B and Secretogranin II are shown as part of a complex
neuroendocrine axis that can ultimately provide resistance to cancer.
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Table 1
Proteomics analysis of secreted proteins from the pituitary of Snell dwarf and control mice
Secreted pituitary proteins by proteomics analysis Control Snell dwarf
Growth hormone + ND
Prolactin + ND
ACTH + +
Chromogranin A + ++
Chromogranin A + ++
Secretogranin II + ++
Proteomics analysis confirmed that the pituitary of the Snell dwarf does not secrete GH or PRL and verified the secretion of ACTH, Chromogranin
A, Chromogranin B and Secretogranin II secretion. LH, FSH and TSH secretion was not detected from Snell dwarf or control and pituitaries. The
plus sign (+) indicates detected, two plus signs (++) indicate a 2-fold difference and ND indicates not detected. Pituitary secretion levels were compared
using quantitative proteomics analysis software (Decyder MS).
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